1	Attenuated	Attenuated	B-NP	NNP	O	4	NMOD
2	Bordetella	Bordetella	I-NP	NNP	O	4	NMOD
3	pertussis	pertussis	I-NP	NN	O	4	NMOD
4	vaccine	vaccine	I-NP	NN	O	5	SUB
5	protects	protect	B-VP	VBZ	O	0	ROOT
6	against	against	B-PP	IN	O	5	VMOD
7	respiratory	respiratory	B-NP	JJ	O	10	NMOD
8	syncytial	syncytial	I-NP	JJ	O	10	NMOD
9	virus	virus	I-NP	NN	O	10	NMOD
10	disease	disease	I-NP	NN	O	6	PMOD
11	via	via	B-PP	IN	O	5	VMOD
12	an	an	B-NP	DT	O	14	NMOD
13	IL-17-dependent	IL-17-dependent	I-NP	JJ	O	14	NMOD
14	mechanism	mechanism	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	attenuated	attenuate	B-VP	VBD	O	0	ROOT
3	virulent	virulent	B-NP	JJ	O	5	NMOD
4	Bordetella	Bordetella	I-NP	NNP	O	5	NMOD
5	pertussis	pertussis	I-NP	NN	O	2	OBJ
6	by	by	B-PP	IN	O	2	VMOD
7	genetically	genetically	B-VP	RB	O	8	VMOD
8	eliminating	eliminate	I-VP	VBG	O	6	PMOD
9	or	or	I-VP	CC	O	8	VMOD
10	detoxifying	detoxify	I-VP	VBG	O	13	NMOD
11	three	three	B-NP	CD	O	13	NMOD
12	major	major	I-NP	JJ	O	13	NMOD
13	toxins	toxin	I-NP	NNS	O	8	VMOD
14	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	strain	strain	I-NP	NN	O	7	SUB
3	,	,	O	,	O	2	P
4	named	name	B-VP	VBN	O	2	NMOD
5	BPZE1	BPZE1	B-NP	NN	B-protein	4	VMOD
6	,	,	O	,	O	2	P
7	is	be	B-VP	VBZ	O	0	ROOT
8	being	be	I-VP	VBG	O	7	VC
9	developed	develop	I-VP	VBN	O	8	VC
10	as	as	B-PP	IN	O	9	VMOD
11	a	a	B-NP	DT	O	15	NMOD
12	possible	possible	I-NP	JJ	O	15	NMOD
13	live	live	I-NP	JJ	O	15	NMOD
14	nasal	nasal	I-NP	JJ	O	15	NMOD
15	vaccine	vaccine	I-NP	NN	O	10	PMOD
16	for	for	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	prevention	prevention	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	whooping	whooping	B-NP	JJ	O	21	NMOD
21	cough	cough	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	7	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	immunogenic	immunogenic	B-ADJP	JJ	O	5	AMOD
4	and	and	I-ADJP	CC	O	5	AMOD
5	safe	safe	I-ADJP	JJ	O	2	PRD
6	when	when	B-ADVP	WRB	O	2	VMOD
7	given	give	B-VP	VBN	O	6	SBAR
8	intranasally	intranasally	B-ADVP	RB	O	7	VMOD
9	in	in	B-PP	IN	O	7	VMOD
10	adult	adult	B-NP	JJ	O	11	NMOD
11	volunteers	volunteer	I-NP	NNS	O	9	PMOD
12	.	.	O	.	O	2	P

1	Before	Before	B-PP	IN	O	8	VMOD
2	testing	testing	B-NP	NN	O	1	PMOD
3	in	in	B-PP	IN	O	2	NMOD
4	human	human	B-NP	JJ	O	5	NMOD
5	infants	infant	I-NP	NNS	O	3	PMOD
6	,	,	O	,	O	8	P
7	we	we	B-NP	PRP	O	8	SUB
8	wished	wish	B-VP	VBD	O	0	ROOT
9	to	to	I-VP	TO	O	10	VMOD
10	examine	examine	I-VP	VB	O	8	VMOD
11	the	the	B-NP	DT	O	13	NMOD
12	potential	potential	I-NP	JJ	O	13	NMOD
13	effect	effect	I-NP	NN	O	10	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	BPZE1	BPZE1	B-NP	NN	B-protein	14	PMOD
16	on	on	B-PP	IN	O	13	NMOD
17	a	a	B-NP	DT	O	20	NMOD
18	common	common	I-NP	JJ	O	20	NMOD
19	pediatric	pediatric	I-NP	JJ	O	20	NMOD
20	infection	infection	I-NP	NN	O	16	PMOD
21	(	(	O	(	O	28	DEP
22	respiratory	respiratory	B-NP	JJ	O	24	NMOD
23	syncytial	syncytial	I-NP	JJ	O	24	NMOD
24	virus	virus	I-NP	NN	O	28	DEP
25	[	[	O	(	O	27	DEP
26	RSV	RSV	B-NP	NN	O	27	DEP
27	]	]	O	)	O	24	NMOD
28	)	)	O	)	O	20	NMOD
29	in	in	B-PP	IN	O	10	VMOD
30	a	a	B-NP	DT	O	32	NMOD
31	preclinical	preclinical	I-NP	JJ	O	32	NMOD
32	model	model	I-NP	NN	O	29	PMOD
33	.	.	O	.	O	8	P

1	BPZE1	BPZE1	B-NP	NN	B-protein	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	administered	administer	I-VP	VBN	O	2	VC
4	before	before	B-PP	IN	O	3	VMOD
5	or	or	I-PP	CC	O	4	PMOD
6	after	after	I-PP	IN	O	4	PMOD
7	RSV	RSV	B-NP	NN	O	8	NMOD
8	administration	administration	I-NP	NN	O	4	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	adult	adult	B-NP	JJ	O	13	NMOD
11	or	or	I-NP	CC	O	13	NMOD
12	neonatal	neonatal	I-NP	JJ	O	13	NMOD
13	mice	mouse	I-NP	NNS	O	9	PMOD
14	.	.	O	.	O	2	P

1	Pathogen	Pathogen	B-NP	NN	O	2	NMOD
2	replication	replication	I-NP	NN	O	13	SUB
3	,	,	O	,	O	13	P
4	inflammation	inflammation	B-NP	NN	O	13	SUB
5	,	,	O	,	O	13	P
6	immune	immune	B-NP	JJ	O	8	NMOD
7	cell	cell	I-NP	NN	O	8	NMOD
8	recruitment	recruitment	I-NP	NN	O	13	SUB
9	,	,	O	,	O	13	P
10	and	and	O	CC	O	13	VMOD
11	cytokine	cytokine	B-NP	NN	B-protein	12	NMOD
12	responses	response	I-NP	NNS	O	13	SUB
13	were	be	B-VP	VBD	O	0	ROOT
14	measured	measure	I-VP	VBN	O	13	VC
15	.	.	O	.	O	13	P

1	BPZE1	BPZE1	B-NP	NN	B-protein	3	SUB
2	alone	alone	B-ADVP	RB	O	1	NMOD
3	did	do	B-VP	VBD	O	0	ROOT
4	not	not	I-VP	RB	O	3	VMOD
5	cause	cause	I-VP	VB	O	3	VC
6	overt	overt	B-NP	JJ	O	7	NMOD
7	disease	disease	I-NP	NN	O	5	OBJ
8	,	,	O	,	O	3	P
9	but	but	O	CC	O	3	VMOD
10	induced	induce	B-VP	VBD	O	3	VMOD
11	efflux	efflux	B-NP	NN	O	10	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	neutrophils	neutrophil	B-NP	NNS	B-cell_type	12	PMOD
14	into	into	B-PP	IN	O	10	VMOD
15	the	the	B-NP	DT	O	17	NMOD
16	airway	airway	I-NP	NN	O	17	NMOD
17	lumen	lumen	I-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	production	production	I-NP	NN	O	14	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	IL-10	IL-10	B-NP	NN	B-protein	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	IL-17	IL-17	I-NP	NN	B-protein	20	PMOD
24	by	by	B-PP	IN	O	19	NMOD
25	mucosal	mucosal	B-NP	JJ	B-cell_type	31	NMOD
26	CD4	CD4	I-NP	NN	I-cell_type	31	NMOD
27	(	(	O	(	I-cell_type	29	DEP
28	+	+	O	SYM	I-cell_type	29	DEP
29	)	)	O	)	I-cell_type	26	NMOD
30	T	T	B-NP	NN	I-cell_type	31	NMOD
31	cells	cell	I-NP	NNS	I-cell_type	24	PMOD
32	.	.	O	.	O	3	P

1	Given	Give	B-VP	VBN	O	9	VMOD
2	intranasally	intranasally	B-ADVP	RB	O	1	VMOD
3	before	before	B-PP	IN	O	1	VMOD
4	RSV	RSV	B-NP	NN	O	5	NMOD
5	infection	infection	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	9	P
7	BPZE1	BPZE1	B-NP	NN	B-protein	9	SUB
8	markedly	markedly	B-ADVP	RB	O	9	VMOD
9	attenuated	attenuate	B-VP	VBD	O	0	ROOT
10	RSV	RSV	B-NP	NN	B-protein	9	OBJ
11	,	,	O	,	O	9	P
12	preventing	prevent	B-VP	VBG	O	9	VMOD
13	weight	weight	B-NP	NN	O	14	NMOD
14	loss	loss	I-NP	NN	O	12	OBJ
15	,	,	O	,	O	9	P
16	reducing	reduce	B-VP	VBG	O	9	VMOD
17	viral	viral	B-NP	JJ	O	18	NMOD
18	load	load	I-NP	NN	O	16	OBJ
19	,	,	O	,	O	24	P
20	and	and	O	CC	O	24	NMOD
21	attenuating	attenuate	B-VP	VBG	O	24	NMOD
22	lung	lung	B-NP	NN	O	24	NMOD
23	cell	cell	I-NP	NN	O	24	NMOD
24	recruitment	recruitment	I-NP	NN	O	9	VMOD
25	.	.	O	.	O	9	P

1	Given	Give	B-VP	VBN	O	6	VMOD
2	neonatally	neonatally	B-ADVP	RB	O	1	VMOD
3	,	,	O	,	O	6	P
4	BPZE1	BPZE1	B-NP	NN	B-protein	6	SUB
5	also	also	B-ADVP	RB	O	6	VMOD
6	protected	protect	B-VP	VBD	O	0	ROOT
7	against	against	B-PP	IN	O	6	VMOD
8	RSV-induced	RSV-induced	B-NP	JJ	O	10	NMOD
9	weight	weight	I-NP	NN	O	10	NMOD
10	loss	loss	I-NP	NN	O	7	PMOD
11	even	even	B-PP	RB	O	12	PMOD
12	through	through	I-PP	IN	O	6	VMOD
13	to	to	B-PP	TO	O	12	PMOD
14	adulthood	adulthood	B-NP	NN	O	12	PMOD
15	.	.	O	.	O	6	P

1	Furthermore	Furthermore	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	it	it	B-NP	PRP	O	5	SUB
4	markedly	markedly	B-ADVP	RB	O	5	VMOD
5	increased	increase	B-VP	VBD	O	0	ROOT
6	IL-17	IL-17	B-NP	NN	B-protein	7	NMOD
7	production	production	I-NP	NN	O	5	OBJ
8	by	by	B-PP	IN	O	5	VMOD
9	CD4	CD4	B-NP	NN	B-cell_type	14	NMOD
10	(	(	O	(	I-cell_type	12	DEP
11	+	+	O	SYM	I-cell_type	12	DEP
12	)	)	O	)	I-cell_type	9	NMOD
13	T	T	B-NP	NN	I-cell_type	14	NMOD
14	cells	cell	I-NP	NNS	I-cell_type	18	NMOD
15	and	and	O	CC	O	18	NMOD
16	natural	natural	B-NP	JJ	B-cell_type	18	NMOD
17	killer	killer	I-NP	NN	I-cell_type	18	NMOD
18	cells	cell	I-NP	NNS	I-cell_type	24	NMOD
19	and	and	O	CC	O	24	NMOD
20	recruited	recruit	B-VP	VBN	B-cell_type	24	NMOD
21	regulatory	regulatory	B-NP	JJ	I-cell_type	22	NMOD
22	cells	cell	I-NP	NNS	I-cell_type	24	NMOD
23	and	and	O	CC	O	24	NMOD
24	neutrophils	neutrophil	B-NP	NNS	B-cell_type	8	PMOD
25	after	after	B-PP	IN	O	5	VMOD
26	virus	virus	B-NP	NN	O	27	NMOD
27	challenge	challenge	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	5	P

1	Administration	Administration	B-NP	NN	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	anti-IL-17	anti-IL-17	B-NP	JJ	B-protein	4	NMOD
4	antibodies	antibody	I-NP	NNS	I-protein	2	PMOD
5	ablated	ablate	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	8	NMOD
7	protective	protective	I-NP	JJ	O	8	NMOD
8	effect	effect	I-NP	NN	O	5	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	BPZE1	BPZE1	B-NP	NN	B-protein	9	PMOD
11	on	on	B-PP	IN	O	5	VMOD
12	RSV	RSV	B-NP	NN	O	13	NMOD
13	disease	disease	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	5	P

1	Rather	Rather	B-PP	RB	O	8	VMOD
2	than	than	I-PP	IN	O	1	PMOD
3	enhancing	enhance	B-VP	VBG	O	2	PMOD
4	RSV	RSV	B-NP	NN	O	5	NMOD
5	disease	disease	I-NP	NN	O	3	OBJ
6	,	,	O	,	O	8	P
7	BPZE1	BPZE1	B-NP	NN	B-protein	8	SUB
8	protected	protect	B-VP	VBD	O	0	ROOT
9	against	against	B-PP	IN	O	8	VMOD
10	viral	viral	B-NP	JJ	O	11	NMOD
11	infection	infection	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	8	P
13	modified	modify	B-VP	VBN	O	8	VMOD
14	viral	viral	B-NP	JJ	O	15	NMOD
15	responses	response	I-NP	NNS	O	13	OBJ
16	,	,	O	,	O	8	P
17	and	and	O	CC	O	8	VMOD
18	enhanced	enhance	B-VP	VBD	O	8	VMOD
19	natural	natural	B-NP	JJ	O	21	NMOD
20	mucosal	mucosal	I-NP	JJ	O	21	NMOD
21	resistance	resistance	I-NP	NN	O	18	OBJ
22	.	.	O	.	O	8	P

1	Prevention	Prevention	B-NP	NN	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	RSV	RSV	B-NP	NN	O	4	NMOD
4	infection	infection	I-NP	NN	O	2	PMOD
5	by	by	B-PP	IN	O	1	NMOD
6	BPZE1	BPZE1	B-NP	NN	B-protein	5	PMOD
7	seems	seem	B-VP	VBZ	O	0	ROOT
8	in	in	B-PP	IN	O	7	VMOD
9	part	part	B-NP	NN	O	8	PMOD
10	to	to	B-VP	TO	O	11	VMOD
11	be	be	I-VP	VB	O	8	SBAR
12	caused	cause	I-VP	VBN	O	11	VC
13	by	by	B-PP	IN	O	12	VMOD
14	induction	induction	B-NP	NN	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	IL-17	IL-17	B-NP	NN	B-protein	15	PMOD
17	.	.	O	.	O	7	P

1	Clinical	Clinical	B-NP	JJ	O	2	NMOD
2	trial	trial	I-NP	NN	O	3	SUB
3	registered	register	B-VP	VBD	O	0	ROOT
4	with	with	B-PP	IN	O	3	VMOD
5	www.clinicaltrials.gov	www.clinicaltrials.gov	B-NP	NN	O	4	PMOD
6	(	(	O	(	O	9	DEP
7	NCT	NCT	B-NP	NN	O	9	DEP
8	01188512	01188512	I-NP	CD	O	7	NMOD
9	)	)	O	)	O	5	NMOD
10	.	.	O	.	O	3	P

